 Connection
Pamela Zeitlin to Chlorides
This is a "connection" page, showing publications Pamela Zeitlin has written about Chlorides.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.550 |
|
|
|
-
Bratcher PE, Yadav S, Shaughnessy CA, Thornell IM, Zeitlin PL. Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Physiol Rep. 2020 10; 8(19):e14603.
Score: 0.654
-
MacDonald KD, McKenzie KR, Henderson MJ, Hawkins CE, Vij N, Zeitlin PL. Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am J Physiol Lung Cell Mol Physiol. 2008 Nov; 295(5):L933-40.
Score: 0.284
-
Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep; 31(3):351-7.
Score: 0.211
-
Paranjape SM, Zeitlin PL. Atypical cystic fibrosis and CFTR-related diseases. Clin Rev Allergy Immunol. 2008 Dec; 35(3):116-23.
Score: 0.072
-
Zeitlin PL. Cystic fibrosis and estrogens: a perfect storm. J Clin Invest. 2008 Dec; 118(12):3841-4.
Score: 0.072
-
Liang L, MacDonald K, Schwiebert EM, Zeitlin PL, Guggino WB. Spiperone, identified through compound screening, activates calcium-dependent chloride secretion in the airway. Am J Physiol Cell Physiol. 2009 Jan; 296(1):C131-41.
Score: 0.072
-
Zeitlin PL. Emerging drug treatments for cystic fibrosis. Expert Opin Emerg Drugs. 2003 Nov; 8(2):523-35.
Score: 0.051
-
Boyle MP, Diener-West M, Milgram L, Knowles M, Foy C, Zeitlin P, Standaert T. A multicenter study of the effect of solution temperature on nasal potential difference measurements. Chest. 2003 Aug; 124(2):482-9.
Score: 0.050
-
Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther. 2002 Jul; 6(1):119-26.
Score: 0.046
-
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014 Jul; 2(7):539-47.
Score: 0.026
-
Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med. 2002 Aug 08; 347(6):401-7.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|